An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

• Bin Xue,
• Yifan Liu,
• Min Zhang,
• Gangfeng Xiao,
• Xiu Luo,
• Lili Zhou,
• Shiguang Ye,
• Yan Lu,
• Wenbin Qian,
• Li Wang,
• Ping Li,
• Aibin Liang,
• Sihan Zhou,
• Xiuyuan Hao

Affiliations

Bin Xue

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Yifan Liu

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Min Zhang

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Gangfeng Xiao

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Xiu Luo

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Lili Zhou

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Shiguang Ye

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Yan Lu

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Wenbin Qian

3 Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China

Li Wang

4 Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China

Ping Li

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Aibin Liang

1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China

Sihan Zhou

Xiuyuan Hao